Therapeutically, targeting m6A regulators—such as through inhibition of METTL3 or FTO—disrupts tumor-intrinsic immune resistance and reshapes extrinsic immunosuppressive networks, thereby enhancing the efficacy of immune checkpoint inhibitors in cold tumor settings [191,192]. The gene discussed is METTL3; the disease is neoplasm.